Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel + nedaplatin + bevacizumab first-line therapy for driver-negative advanced lung adenocarcinoma
ChiCTR1800020333Phase 2Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Jan 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, nedaplatin and bevacizumab in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Tongji Hospital. Primary endpoint: Objective response rate. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
paclitaxelnedaplatinbevacizumab
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800020333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020333.